Terms: = Endocrine gland cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
62 results:
1. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic cancer.
Pourali G; Zafari N; Velayati M; Mehrabadi S; Maftooh M; Hassanian SM; Mobarhan MG; Ferns GA; Avan A; Khazaei M
Curr Drug Targets; 2023; 24(17):1335-1345. PubMed ID: 38053355
[TBL] [Abstract] [Full Text] [Related]
3. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma.
Zhang Z; Zhu XQ; Yang F; Lai NN; Zhu L; Cole K; Hu BY; Li TE; Zhu Y; Zhang LM; Wang S; Zheng Y; Mao H; Zhao Y; Bruns C; Vago R; Tu B; Wong JWH; Fu DL; Qin LX; Dong QZ
Med; 2023 Oct; 4(10):728-743.e7. PubMed ID: 37633269
[TBL] [Abstract] [Full Text] [Related]
4. The prognostic role of epidermal growth factor receptor mutation in completely resected ampullary adenocarcinoma.
Varol U; Cakır E; Aktas S; Altun ZS; Dilek FH; Butun O; Salman T; Unlu AGD; Alacacioglu A; Somali I
Pol J Pathol; 2023; 74(1):18-28. PubMed ID: 37306349
[TBL] [Abstract] [Full Text] [Related]
5. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
6. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
[TBL] [Abstract] [Full Text] [Related]
7. Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic cancer After Neoadjuvant Therapy: A Report of 36 Consecutive Cases.
Liang T; Zhang Q; Wu G; Liu C; Bai X; Gao S; Ma T; Sun K; Yan S; Xiao W; Jiang T; Lu F; Zhang Y; Shen Y; Zhang M; Zhang X; Shan J
Ann Surg; 2023 Nov; 278(5):e1055-e1062. PubMed ID: 36727746
[TBL] [Abstract] [Full Text] [Related]
8. Long-term response to camrelizumab in a pretreated metastatic mixed testicular germ-cell tumor patient with co-mutations in DNA damage-repair genes.
Zhang H; Jiang D; Meng E; Zhao M; Niu B
Immunotherapy; 2023 Jan; 15(1):17-25. PubMed ID: 36647794
[TBL] [Abstract] [Full Text] [Related]
9. Case report: Two PD-L1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after pd-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases.
Shang L; Li P; Fan J; Zhao C; Niu X; Bian Q; Yuan Z; Kong Y; Zhu T; Xu B; Dong J; Xiang H
Front Immunol; 2022; 13():946266. PubMed ID: 36203575
[TBL] [Abstract] [Full Text] [Related]
10. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract] [Full Text] [Related]
11. Targeting pd-1/PD-L1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract] [Full Text] [Related]
12. Top Ten Tips Palliative Care Clinicians Should Know About Managing Immune-Mediated endocrine Toxicities in cancer.
Ferreira MN; Rao M; Kamal AH; Shariff A
J Palliat Med; 2022 Nov; 25(11):1715-1720. PubMed ID: 35696238
[TBL] [Abstract] [Full Text] [Related]
13. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
[TBL] [Abstract] [Full Text] [Related]
14. Biomarkers of Central Nervous System Involvement from Epithelial Ovarian cancer.
Scotto G; Borella F; Turinetto M; Tuninetti V; Valsecchi AA; Giannone G; Cosma S; Benedetto C; Valabrega G
Cells; 2021 Dec; 10(12):. PubMed ID: 34943916
[TBL] [Abstract] [Full Text] [Related]
15. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review.
Sun N; Zhang J; Li B; Li A; Lv M; Zhang C
Medicine (Baltimore); 2021 Dec; 100(49):e27987. PubMed ID: 34889243
[TBL] [Abstract] [Full Text] [Related]
16. Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy.
Takeda T; Tsuji K; Kobayashi Y; Banno K; Aoki D
Jpn J Clin Oncol; 2022 Feb; 52(2):128-133. PubMed ID: 34750611
[TBL] [Abstract] [Full Text] [Related]
17. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis.
Seejore K; Giannoudi M; Osborn D; Lynch JM; Al-Qaissi A; Dunwoodie E; Hook J; Marples M; Murray RD
Eur J Endocrinol; 2021 Dec; 186(1):83-93. PubMed ID: 34735371
[TBL] [Abstract] [Full Text] [Related]
18. Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer.
Nero C; Romito I; Spadola S; Romito A; Turco LC; Cosentino F; De Ninno M; Catena U; De Cicco Nardone A; Moroni R; Zannoni G; Fagotti A; Scambia G
Fertil Steril; 2022 Jan; 117(1):160-168. PubMed ID: 34656305
[TBL] [Abstract] [Full Text] [Related]
19. A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target.
Xu JL; Guo Y
Invest New Drugs; 2022 Feb; 40(1):58-67. PubMed ID: 34515878
[TBL] [Abstract] [Full Text] [Related]
20. Antitumor immune response is associated with favorable survival in GEP-NEN G3.
Rosery V; Reis H; Savvatakis K; Kowall B; Stuschke M; Paul A; Dechêne A; Yang J; Zhao B; Borgers A; Kasper S; Schuler M; Cheung PF; Siveke JT
Endocr Relat Cancer; 2021 Sep; 28(10):683-693. PubMed ID: 34472429
[TBL] [Abstract] [Full Text] [Related]
[Next]
